Status: Recruiting
Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel
This Phase 2, open-label study will evaluate the safety, tolerability, and pharmacokinetics of SIR2501 in adults with solid tumors who are scheduled to receive paclitaxel-based chemotherapy. The study will also explore whether SIR2501 has the potential to reduce the development of chemotherapy-induced peripheral neuropathy (CIPN).
Participants needed: 18
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Sironax USA, Inc.Updated: Oct 9, 2026Locations: 5
Eligibility criteria
Adults ≥18 years with confirmed solid tumors [+2]
Pre-existing peripheral neuropathy [+4]